Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort.

D'Aiello, Angelica; Lin, Juan; Gucalp, Rasim; Tabatabaie, Vafa; Cheng, Haiying; Bloomgarden, Noah A; Tomer, Yaron; Halmos, Balazs

D'Aiello, Angelica; Lin, Juan; Gucalp, Rasim; Tabatabaie, Vafa; Cheng, Haiying; Bloomgarden, Noah A; Tomer, Yaron; Halmos, Balazs.

Afiliação

D'Aiello A; Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USA.
Lin J; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Gucalp R; Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Tabatabaie V; Division of Endocrinology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USA.
Cheng H; Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Bloomgarden NA; Division of Endocrinology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USA.
Tomer Y; Division of Endocrinology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USA.
Halmos B; Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Cancers (Basel) ; 13(6)2021 Mar 23.

Article em En | MEDLINE | ID: mdl-33806774

Palavras-chave

NSCLC; SCLC; checkpoint inhibitors; immune-related adverse events; immunotherapy; thyroid

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google